Treatment of the genitourinary syndrome of menopause

References

• Smith P. Estrogens and the urogenital tract studies on steroid hormone receptors and a clinical study on a new estradiol releasing vaginal ring. Acta Obstet Gynecol Scand Suppl 1993;157:1–26
   PubMedGoogle Scholar
• Archer DF. Efficacy and tolerability of local estrogen therapy for urogenital atrophy. Menopause 2010;17:194–203
   PubMed Web of Science ®Google Scholar
• Al-Baghdadi O, Ewies AA. Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date overview. Climacteric 2009;12:91–105
   PubMed Web of Science ®Google Scholar
• Nappi RE, Lachowsky M. Menopause and sexuality: prevalence of symptoms and impact on quality of life. Maturitas 2009;63:138–41
   PubMed Web of Science ®Google Scholar
• Portman DJ, Gass ML;Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and The North American Menopause Society. Climacteric 2014;17:557–63
   PubMed Web of Science ®Google Scholar
• Rosa Lima SMR, Botogoski SR, do Reis BF. Menopausa, o que voce precisa saber, 2nd edn. Sao Paulo: Atheneu Editora, 2014, Chapter 24
   Google Scholar
• Palacios S. Managing urogenital atrophy. Maturitas 2009;63: 315–18
   PubMed Web of Science ®Google Scholar
• Kingsberg SA, Wysocki S, Magnus L, Krychman ML. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (Real Women’s Views of Treatment Options for Menopausal Vaginal Changes) survey. J Sex Med 2013;10:1790–9
   PubMed Web of Science ®Google Scholar
• Leiblum S, Bachmann G, Kemmann E, Colburn D, Swartzman L. Vaginal atrophy in the postmenopausal woman. The importance of sexual activity and hormones. JAMA 1983;249:2195–8
   PubMed Web of Science ®Google Scholar
• Castelo-Branco C, Cancelo MJ, Villero J, Nohales F, Juliá MD. Management of post-menopausal vaginal atrophy and atrophic vaginitis. Maturitas 2005;52(Suppl 1):S46–52
   PubMed Web of Science ®Google Scholar
• Nachtigall E. Comparative study: Replens versus local estrogen in menopausal women. Fertil Steril 1994;61:178–80
   PubMed Web of Science ®Google Scholar
• Manonai J, Songchitsomboon S, Chanda K, Hong JH, Komindr S. The effect of a soy-rich diet on urogenital atrophy: a randomized crossover trial. Maturitas 2006;54:135–40
   PubMed Web of Science ®Google Scholar
• Hidalgo LA, Chedraui PA, Morocho N, Ross S, San Miguel G. The effect of red clover isoflavones on menopausal symptoms, lipids and vaginal cytology in menopausal women: a randomized, double-blind, placebo-controlled study. Gynecol Endocrinol 2005;21:257–64
   PubMed Web of Science ®Google Scholar
• The 2012 Hormone Therapy Position Statement of The North American Menopause Society. Menopause 2012;19:257–71
   PubMed Web of Science ®Google Scholar
• Cardozo L, Bachmann G, McGlish D, Fonda D, Birgerson L. Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: Second Report of hormones and Urogenital Therapy Committee. Obstet Gynecol 1998:92:722–7
   PubMed Web of Science ®Google Scholar
• Barnabei VM, Cochrane BB, Aragaki AK, et al. Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative. Obstet Gynecol 2005;105: 1063–73
   PubMed Web of Science ®Google Scholar
• Sturdee DW, Panay N; International Menopause Society Writing Group. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric 2010;13:509–22
   PubMed Web of Science ®Google Scholar
• Lobo RA, Pinkerton JV, Gass ML, et al. Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Fertil Steril 2009;92:1025–38
   PubMed Web of Science ®Google Scholar
• Pinkerton JV, Utian WH, Constantine GD, Olivier S, Pickar JH. Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial. Menopause 2009;16:1116–24
   PubMed Web of Science ®Google Scholar
• Kagan R, Williams RS, Pan K, Mirkin S, Pickar JH. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women. Menopause 2010;17:281–9
   PubMed Web of Science ®Google Scholar
• Suckling JA, Kennedy R, Lethaby A, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2006, Issue 4. Art. No.: CD001500
   PubMed Web of Science ®Google Scholar
• McCall JL, DeGregorio MW. Pharmacologic evaluation of ospemifene. Expert Opin Drug Metab Toxicol 2010;6:773–9
   PubMed Web of Science ®Google Scholar
• Bachmann GA, Komi JO; Ospemifene Study Group. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause 2010; 17:480–6
   PubMed Web of Science ®Google Scholar
• Simon JA, Lin VH, Radovich C, Bachmann GA; The Ospemifene Study Group. One year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus. Menopause 2013;20:418–27
   PubMed Web of Science ®Google Scholar
• Portman DJ, Bachmann GA, Simon JA; Ospemifene Study Group. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause 2013;20:623–30
   PubMed Web of Science ®Google Scholar
• Portman D, Palacios S, Nappi RE, Mueck AO. Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial. Maturitas 2014;78:91–8
   PubMed Web of Science ®Google Scholar
• Min Seok Lee. Treatment of vaginal relaxation syndrome with an erbium:YAG laser using 90° and 360° scanning scopes: a pilot study & short-term results. Laser Ther 2014;23:129–38
   PubMedGoogle Scholar
• Salvatore S, Nappi RE, Zerbinati N, et al. A 12-week treatment with fractional CO2 laser for vulvovaginal atrophy: a pilot study. Climacteric 2014;17:363–9
   PubMed Web of Science ®Google Scholar
• Salvatore S, Nappi RE, Parma M, et al. Sexual function after fractional microablative CO2 laser in women with vulvovaginal atrophy. Climacteric 2015;18:219–25
   PubMed Web of Science ®Google Scholar
• Zerbinati N, Serati M Origoni M, et al. Microscopic and ultrastructural modifications of postmenopausal atrophic vaginal mucosa after fractional carbon dioxide laser treatment. Laser Med Sci 2015; 30:429–36
   PubMed Web of Science ®Google Scholar
• Perino A, Calligaro A, Forlani F, et al. Vulvo-vaginal atrophy: A new treatment modality using thermo-ablative fractional CO2 laser. Maturitas 2015;80:296–301
   PubMed Web of Science ®Google Scholar
• Pessina MA, Hoyt RF, Goldstein I, Traish AM. Differential regulation of the expression of estrogen, progesterone, and androgen receptor by sex steroid hormones in the vagina: Immunohistochemical studies. J Sex Med 2006;3:804–14
   PubMed Web of Science ®Google Scholar
• Krapf JM, Simon JA. The role of testosterone in the management of hypoactive sexual desire disorder in postmenopausal women. Maturitas 2009;63:213–19
   PubMed Web of Science ®Google Scholar
• Baldassarre M, Perrone AM, Giannone FA, et al. Androgen receptor expression in the human vagina under different physiological and treatment conditions. Int J Impot Res 2013; 25:7–11
   PubMed Web of Science ®Google Scholar
• Traish AM, Kim N, Min K, Muarriz R, Goldstein I. Role of androgens in female genital sexual arousal: receptor expression, structure and function. Fertil Steril 2002;77:S11–18
   PubMed Web of Science ®Google Scholar
• Panjani M, Bell RJ, Jane F, et al. A randomized trial of oral DHEA treatment for sexual function, well-being, and menopausal symptoms in postmenopausal women with low libido. J Sex Med 2009;6:2579–90
   PubMed Web of Science ®Google Scholar
• Labrie F, Cusan L, Gomez JL, et al. Effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women. J Steroid Biochem Mol Biol 2008;111:178–94
   PubMed Web of Science ®Google Scholar
• Labrie F, Archer D, Bouchard C, et al. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual function in postmenopausal women. Menopause 2009;16:923–31
   PubMed Web of Science ®Google Scholar
• Labrie F, Archer D, Bouchard C, et al. Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia. Climacteric 2011;14:282–8
   PubMed Web of Science ®Google Scholar
• Labrie F, Archer DF, Bouchard C, et al. Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study. Maturitas 2015;81:46–56
   PubMed Web of Science ®Google Scholar